Cargando…

Oral anticoagulant treatment after bioprosthetic valvular intervention or valvuloplasty in patients with atrial fibrillation—A SWEDEHEART study

AIMS: To describe the prevalence of atrial fibrillation (AF), use of oral anticoagulants (OAC) and change in antithrombotic treatment patterns during follow-up after valve intervention with a biological prosthesis or valvuloplasty. METHODS AND RESULTS: All patients with history of AF or new-onset AF...

Descripción completa

Detalles Bibliográficos
Autores principales:	Christersson, Christina, Held, Claes, Modica, Angelo, Westerbergh, Johan, Batra, Gorav
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8757947/ https://www.ncbi.nlm.nih.gov/pubmed/35025950 http://dx.doi.org/10.1371/journal.pone.0262580

Ejemplares similares

Oral anticoagulants, time in therapeutic range and renal function over time in real-life patients with atrial fibrillation and chronic kidney disease
por: Batra, Gorav, et al.
Publicado: (2022)

Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
por: da Silva, Rose M.F.L.
Publicado: (2014)

Bioprosthetic Valve Thrombosis while on a Novel Oral Anticoagulant for Atrial Fibrillation
por: O'Callaghan, Marissa, et al.
Publicado: (2018)

Balloon Valvuloplasty for Bioprosthetic Tricuspid Valve Stenosis
por: Petrou, Emmanouil, et al.
Publicado: (2014)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
por: Harburger, Joseph M., et al.
Publicado: (2012)

Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation
por: Lindley, Richard I
Publicado: (2021)

Oral anticoagulation following bioprosthetic SAVR in patients with atrial fibrillation: what’s the current status of NOACs?
por: Milojevic, Milan, et al.
Publicado: (2022)

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial
por: Pol, Tymon, et al.
Publicado: (2018)

Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions
por: Di Biase, Luigi
Publicado: (2016)

Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Bioprosthetic Valves—A Systematic Review and Meta-analysis
por: Ruzieh, Mohammed, et al.
Publicado: (2021)

Effectiveness and safety of non-vitamin K direct oral anticoagulants in atrial fibrillation patients with bioprosthetic valve
por: Moon, Inki, et al.
Publicado: (2022)

Assessing the external validity of the VALIDATE-SWEDEHEART trial
por: Rylance, Rebecca T, et al.
Publicado: (2021)

Suboptimal oral anticoagulant treatment among Chinese non-valvular atrial fibrillation patients: the Nanchang Atrial Fibrillation Project
por: Xiong, Qinmei, et al.
Publicado: (2016)

Risk Stratification and Anticoagulation in Low-risk Non-valvular Atrial Fibrillation
por: Arya, Arash
Publicado: (2013)

Anticoagulation Therapy for Non-valvular Atrial Fibrillation: A Mini-Review
por: Wu, Jia, et al.
Publicado: (2020)

Anticoagulant Prescribing for Non‐Valvular Atrial Fibrillation in the Veterans Health Administration
por: Rose, Adam J., et al.
Publicado: (2019)

Real-World Data of Anticoagulant Treatment in Non-valvular Atrial Fibrillation
por: Calderon, Jose Miguel, et al.
Publicado: (2022)

Trials of Novel Oral Anticoagulants for Stroke Prevention In Patients with Non-valvular Atrial Fibrillation
por: Halperin, Jonathan L, et al.
Publicado: (2014)

Psychological effects of treatment with novel oral anticoagulants in non-valvular atrial fibrillation patients
por: Öncel, Can Ramazan
Publicado: (2016)

Direct oral anticoagulants and the risk of osteoporotic fractures in patients with non-valvular atrial fibrillation
por: Kuo, Liang-Tseng, et al.
Publicado: (2021)

Non-persistence to Oral Anticoagulation Treatment in Patients with Non-valvular Atrial Fibrillation in the USA
por: Dhamane, Amol D, et al.
Publicado: (2021)

Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation
por: Hwang, Ki Won, et al.
Publicado: (2023)

ABO blood type and risk of porcine bioprosthetic aortic valve degeneration: SWEDEHEART observational cohort study
por: Persson, Michael, et al.
Publicado: (2019)

Reliability of estimating left ventricular ejection fraction in clinical routine: a validation study of the SWEDEHEART registry
por: Lenell, Joel, et al.
Publicado: (2022)

Indications for suboptimal low-dose direct oral anticoagulants for non-valvular atrial fibrillation patients
por: Umei, Masahiko, et al.
Publicado: (2017)

Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure
por: Amin, Alpesh, et al.
Publicado: (2019)

Prescribers’ perceptions of benefits and limitations of direct acting oral anticoagulants in non-valvular atrial fibrillation
por: Generalova, Daria, et al.
Publicado: (2020)

Changing trends in the use of novel oral anticoagulants and warfarin for treating non-valvular atrial fibrillation
por: Birkinshaw, Alexander, et al.
Publicado: (2020)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Oral Anticoagulation in Patients with Chronic Kidney Disease and Non-Valvular Atrial Fibrillation: The FAERC Study
por: Montomoli, Marco, et al.
Publicado: (2022)

Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity
por: Dhamane, Amol D., et al.
Publicado: (2022)

Use of Anticoagulants in Patients With Non-Valvular Atrial Fibrillation Who Are at Risk of Falls
por: Shanah, Layla, et al.
Publicado: (2020)

Factors Associated with Anticoagulation Adherence in Chinese Patients with Non-Valvular Atrial Fibrillation
por: Song, Ting, et al.
Publicado: (2021)

The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)

Comparison Between Oral Anticoagulation and Left Atrial Appendage Occlusion in the Prevention of Stroke With Regard to Non-Valvular Atrial Fibrillation
por: Sandhu, Osama, et al.
Publicado: (2020)

Erratum to: The Global Anticoagulant Registry in the FIELD – Atrial Fibrillation (GARFIELD-AF): Exploring the changes in anticoagulant practice in patients with non-valvular atrial fibrillation in the Netherlands
por: ten Cate, V., et al.
Publicado: (2016)

Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai
por: Liu, Feng-Di, et al.
Publicado: (2016)

Oral Anticoagulants Preference in Hospitalized Patients with Acute Deep Vein Thrombosis or Non-Valvular Atrial Fibrillation
por: Vesa, Ştefan Cristian, et al.
Publicado: (2020)

Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_l237o3hqosmtq8e36slb82ocnv